Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cardiff Oncology (CRDF) Cash from Restructuring (2017 - 2018)

Cardiff Oncology (CRDF) has disclosed Cash from Restructuring for 2 consecutive years, with $187500.0 as the latest value for Q2 2018.

  • Quarterly Cash from Restructuring changed N/A to $187500.0 in Q2 2018 from the year-ago period, while the trailing twelve-month figure was $187500.0 through Sep 2019, down 35.83% year-over-year, with the annual reading at $34000.0 for FY2020, N/A changed from the prior year.
  • Cash from Restructuring hit $187500.0 in Q2 2018 for Cardiff Oncology, up from $104700.0 in the prior quarter.
  • In the past five years, Cash from Restructuring ranged from a high of $485000.0 in Q1 2017 to a low of $104700.0 in Q4 2017.